APG Asset Management N.V. - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
APG Asset Management N.V. ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$8,773,747
-13.4%
128,893
-4.8%
0.02%
-10.0%
Q2 2023$10,125,936
+7.4%
135,335
-2.0%
0.02%0.0%
Q1 2023$9,432,431
+69821.7%
138,130
-15.1%
0.02%
-23.1%
Q4 2022$13,490
-99.4%
162,767
+2074.6%
0.03%
+333.3%
Q3 2022$2,170,000
+26.5%
7,485
+44.6%
0.01%
+50.0%
Q2 2022$1,716,000
-4.1%
5,175
+12.5%
0.00%
+33.3%
Q1 2022$1,790,000
-19.7%
4,600
-6.1%
0.00%
-25.0%
Q4 2021$2,229,000
-40.8%
4,900
-45.6%
0.00%
-42.9%
Q3 2021$3,763,000
+70.9%
9,000
+55.2%
0.01%
+75.0%
Q2 2021$2,202,0005,8000.00%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2022
NameSharesValueWeighting ↓
ROWLANDMILLER & PARTNERS.ADV 47,975$3,701,7510.85%
Diversified Trust Co 13,882$1,071,1350.04%
Czech National Bank 27,698$2,137,1780.03%
FULTON BANK, N.A. 5,444$420,0580.02%
DnB Asset Management AS 27,637$2,132,4710.01%
Versant Capital Management, Inc 36$2,7780.00%
MASSMUTUAL TRUST CO FSB/ADV 371$28,6260.00%
Bartlett & Co. LLC 172$130.00%
View complete list of BIO-TECHNE CORP shareholders